{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:59:22Z","timestamp":1768525162155,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI102639"],"award-info":[{"award-number":["K23AI102639"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI104441"],"award-info":[{"award-number":["R21AI104441"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ijid.2017.12.017","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T13:12:49Z","timestamp":1513343569000},"page":"18-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment"],"prefix":"10.1016","volume":"68","author":[{"given":"Isaac","family":"Zentner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chawangwa","family":"Modongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola M.","family":"Zetola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jotam G.","family":"Pasipanodya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott K.","family":"Heysell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stellah","family":"Mpagama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans P.","family":"Schlect","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Bisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0641-7814","authenticated-orcid":false,"given":"Christopher","family":"Vinnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2017.12.017_bib0005","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","article-title":"Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians","volume":"19","author":"Carpenter","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.ijid.2017.12.017_bib0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.03931-14","article-title":"Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis","volume":"59","author":"Chigutsa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.12.017_bib0020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1086\/318706","article-title":"A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes","volume":"32","author":"El-Sadr","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0025","first-page":"S343","article-title":"The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules","volume":"3","author":"Ellard","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0030","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics\u2013pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.12.017_bib0035","first-page":"129","article-title":"Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids","volume":"71","author":"Gurumurthy","year":"1980","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijid.2017.12.017_bib0040","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.5588\/ijtld.16.0048","article-title":"Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India","volume":"20","author":"Hemanth Kumar","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/651686","article-title":"Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis","volume":"50","author":"Khan","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/375220","article-title":"Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review","volume":"37","author":"Korenromp","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0055","first-page":"455","article-title":"The impact of HIV infection on recurrence of tuberculosis in South African gold miners","volume":"4","author":"Mallory","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0060","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1128\/AAC.05526-11","article-title":"Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines","volume":"56","author":"McIlleron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.12.017_bib0065","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0070","doi-asserted-by":"crossref","first-page":"e45913","DOI":"10.1371\/journal.pone.0045913","article-title":"Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients","volume":"7","author":"Nicolau","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.12.017_bib0075","doi-asserted-by":"crossref","DOI":"10.1177\/2054270414531121","article-title":"Therapeutic drug monitoring in a developing nation: a clinical guide","volume":"5","author":"Nwobodo","year":"2014","journal-title":"JRSM Open"},{"key":"10.1016\/j.ijid.2017.12.017_bib0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy","volume":"55","author":"Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0085","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0090","series-title":"The statistical analysis of medical tests for classification and prediction","author":"Pepe","year":"2003"},{"key":"10.1016\/j.ijid.2017.12.017_bib0095","first-page":"691","article-title":"The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations","volume":"5","author":"Pillai","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0100","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.12.017_bib0105","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/bcp.13172","article-title":"Isoniazid clearance is impaired among human immunodeficiency virus\/tuberculosis patients with high levels of immune activation","volume":"83","author":"Vinnard","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2017.12.017_bib0110","series-title":"Treatment of tuberculosis guidelines","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.ijid.2017.12.017_bib0115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12879-016-1576-1","article-title":"Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study","volume":"16","author":"Zentner","year":"2016","journal-title":"BMC Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217303296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217303296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:39:14Z","timestamp":1761118754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971217303296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":23,"alternative-id":["S1201971217303296"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2017.12.017","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2017.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}